AnaptysBio Inc. has announced new positive results from a Phase 2b clinical trial evaluating rosnilimab, a selective pathogenic T cell depleter, in patients with rheumatoid arthritis. The late-breaking data were presented at the American College of Rheumatology $(ACR)$ Convergence 2025 in Chicago. The study included 424 patients and demonstrated that rosnilimab produced sustained clinical responses, including CDAI remission, from Week 12 to Week 28, regardless of prior advanced therapy. The clinical benefits were durable for at least three months following discontinuation of the drug. Updated safety data through Week 38 indicated that rosnilimab was well-tolerated, with no treatment-related serious adverse events or malignancies reported in patients receiving the drug. The presentation is available for download on the AnaptysBio website.